Dimopoulos, Meletios
Sonneveld, Pieter
Manier, Salomon
Lam, Annette
Roccia, Tito
Schecter, Jordan M.
Cost, Patricia
Pacaud, Lida
Poirier, Abbey
Tremblay, Gabriel
Lan, Tommy
Valluri, Satish
Kumar, Shaji
Funding for this research was provided by:
This work was funded by Janssen Research and Development, LLC, and Legend Biotech USA Inc.
Article History
Received: 15 December 2023
Accepted: 15 April 2024
First Online: 29 April 2024
Declarations
:
: Not applicable.
: MD: Consultancy and honoraria from Amgen, Takeda, Janssen-Cilag, Bristol Myers Squibb, BeiGene, and Sanofi. PS: Consultancy, honoraria, and research funding from Amgen, Celgene/Bristol Myers Squibb, Janssen, Karyopharm, Takeda; Honoraria and research funding from SkylineDx. SM: Consultancy for AbbVie, Adaptive Biotechnology, Amgen, Celgene/Bristol Myers Squibb, GlaxoSmithKline, Janssen, Novartis, Oncopeptide, Regeneron, Roche, Takeda. AL: Employed by Janssen. TR: Previously employed by Janssen; current employee of Regeneron. JMS and PC: Employed by and owns stock in Janssen. LP: Previously employed by Legend Biotech USA Inc; current employee of Ichnos Sciences Inc. AP, GT, and TL: Employed by Cytel Inc. SV: Previously employed by Janssen; current employee of Bristol Myers Squibb. SK: Consultancy and research funding from BMS, AbbVie, Amgen, Takeda, Janssen, KITE, Astra-Zeneca, Roche-Genentech; Research funding from Tenebio, Carsgen, Merck, Novartis; Consultancy at Beigene, Bluebird Bio, Oncopeptides; Consultancy and honoraria from Antengene.
: Not applicable.
: No competing interest to be declared.